Neurowave launches neuromodulation device for postoperative nausea
This article was originally published in Clinica
Neurowave Medical Technologies has launched Reletex, a transdermal neuromodulation device designed to treat postoperative nausea, in the US. The device is worn on the wrist and generates electrical pulses that stimulate the centre of nausea control in the brain, Neurowave claims. This produces anti-nausea signals that travel from the vagus nerve to the digestive system. Reletex provides “almost immediate” relief to patients, the Chicago, Illinois-based firm said, adding that almost every patient undergoing surgery suffers from nausea. The device is cleared by the US FDA as an adjunct to anti-emetic drugs for postoperative nausea. It could reduce the need for these drugs, thereby minimising side-effects and drug interactions, Neurowave believes. The firm also markets devices for other types of nausea, including morning sickness and motion sickness.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.